Active — Not RecruitingNot Applicable

Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD

Australia, France, Germany600 participantsStarted 2020-11-01

Plain-language summary

The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation between the most prevalent fibrotic interstitial lung diseases. The value of eNose as biomarker for disease progression and response to treatment is also assessed. Besides, validity of several questionnaires for pulmonary fibrosis is investigated.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with a diagnosis of fibrotic ILD, as discussed in a multidisciplinary team meeting (50% incident patients and 50% prevalent patients). Patients are classified as 'incident' if they received a diagnosed in a multidisciplinary team meeting within the past six months. Patients will be required to have fibrosis on a HRCT scan \<1 year before enrollment in the study defined as reticular abnormality with traction bronchiectasis, with or without honeycombing, as determined by a radiologist. No minimum extent of fibrosis will be required. Exclusion Criteria: * Alcohol consumption ≤ 12 hours before the measurement * Physically not able to perform eNose measurement

What they're measuring

Diagnostic accuracy for IPF - CHP

Timeframe: Baseline

AUC for IPF - CHP

Timeframe: Baseline

AUC for IPF - iNSIP

Timeframe: Baseline

Diagnostic accuracy for IPF - iNSIP

Timeframe: Baseline

AUC for IPF - IPAF

Timeframe: Baseline

Diagnostic accuracy for IPF - IPAF

Timeframe: Baseline

Diagnostic accuracy for IPF - CTD-ILD

Timeframe: Baseline

AUC for IPF - CTD-ILD

Timeframe: Baseline

Diagnostic accuracy for IPF - unclassifiable ILD

Timeframe: Baseline

Trial details

NCT IDNCT04680832

SponsorErasmus Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Pulmonary Fibrosis trials

Plain-language summary

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Diagnostic accuracy for IPF - CHP

Timeframe: Baseline

AUC for IPF - CHP

Timeframe: Baseline

AUC for IPF - iNSIP

Timeframe: Baseline

Diagnostic accuracy for IPF - iNSIP

Timeframe: Baseline

AUC for IPF - IPAF

Timeframe: Baseline

Diagnostic accuracy for IPF - IPAF

Timeframe: Baseline

Diagnostic accuracy for IPF - CTD-ILD

Timeframe: Baseline

AUC for IPF - CTD-ILD

Timeframe: Baseline

Diagnostic accuracy for IPF - unclassifiable ILD

Timeframe: Baseline